Twist Bioscience stock holds near 52-week high after CEO share sale

Published on 09/22/2026 at 02:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Twist Bioscience stock is trading close to its 52-week high as of September 21, 2026 after a major share sale by CEO Emily Leproust. The company’s recent revenue growth and ongoing losses frame the risk-reward profile for investors.

TWST, US90130A1016, Illustration mit AI erstellt.

Twist Bioscience stock (ISIN US90130A1016) is trading near the top of its recent range, with the share price around USD 165.83 on Nasdaq as of September 21, 2026, close to a 52-week high of USD 167.05 and following a roughly 499% gain over the past year, according to Investing.com on September 21, 2026.

CEO share sale adds a new talking point

The immediate catalyst for Twist Bioscience stock is a substantial share sale by CEO Emily Leproust, who disposed of company shares valued at about USD 56.3 million as highlighted by Investing.com on September 21, 2026.

For investors, the notable point is that this insider transaction comes at a time when the stock is trading around USD 165.83, very close to the 52-week high of USD 167.05 and after an approximate 499% share price increase over the past 12 months, according to the same Investing.com report.

Additional insider activity underlines rich valuation

Alongside the CEO’s sale, further insider-related activity has been disclosed: officer Dennis H. Cho filed a Rule 144 notice for the potential sale of 348 shares of Twist Bioscience common stock, restricted stock that vested on September 18, 2026, with an indicated value of USD 57,591.01 as of September 21, 2026, according to StockTitan.

The same filing notes that Twist Bioscience common stock is listed on Nasdaq, reinforcing the exchange context for the USD-denominated share price used as the reference in this article, as reported by StockTitan.

Fundamentals: strong growth, ongoing losses

Beyond insider transactions, the underlying fundamentals from the most recently reported quarter continue to shape how investors view Twist Bioscience stock. In its latest fiscal quarter for the period ended within the past nine months, Twist Bioscience reported substantial year-over-year revenue growth while still posting a net loss; the company’s investor-relations materials on Twist Bioscience outline a business model focused on synthetic DNA and genomics tools, which has driven rising sales but requires continued investment.

Historical context from prior fiscal years shows that the company has grown revenue strongly from earlier levels while narrowing losses over time, although the most recent quarter still featured a negative operating margin, based on figures summarized across its latest financial communications on Twist Bioscience.

Stock near 52-week high after 499% yearly gain

From a market perspective, the sharp 499% increase in the share price over the past year and the present level around USD 165.83 place Twist Bioscience stock very close to its 52-week high of USD 167.05, according to Investing.com.

That proximity to the high illustrates how strongly the market has rerated the company in the last twelve months, with the implied market capitalization correspondingly much higher than in prior years when the share price was significantly lower, based on the performance and valuation commentary provided by Investing.com.

Closing check: price level and investor takeaway

As of September 21, 2026, Twist Bioscience stock is quoted around USD 165.83 on Nasdaq, close to its 52-week high of USD 167.05, with the past-year performance up approximately 499 percent, according to Investing.com, underlining that the current insider sales are taking place at historically elevated price levels.